ADRB3 Inhibitors
1 drugsAbout ADRB3
The adrenergic beta-3 receptor, or ADRB3, is a G protein-coupled receptor (GPCR) involved in the sympathetic nervous system. It influences lipolysis and thermogenesis, making it a potential drug target.
Currently, there is no genetic evidence directly linking ADRB3 to specific diseases, limiting confidence in target validation.
ADRB3 is targeted by one FDA-approved drug, GEMTESA (SUMITOMO PHARMA AM), a small molecule approved in 2020 for an 'other' therapeutic area.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Obesity with only 1 trials.
Top Drugs
SUMITOMO PHARMA AM is the only company with an approved drug targeting ADRB3.
Low competition may present an opportunity, but also indicates potential challenges in the target's viability.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ADRB3, using small molecule modality.
Explore opportunities for novel modalities like antibodies or peptides to differentiate from existing small molecule approaches.
Clinical Trials 33 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 14 | 10 | 2 | 2 | 83% |
| Phase 2 | 5 | 4 | 0 | 1 | 100% |
| Phase 3 | 10 | 7 | 0 | 3 | 100% |
| Phase 4 | 4 | 2 | 1 | 1 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved ADRB3 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting ADRB3. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2020 - 2020)
GEMTESA was the first and most recent drug approved in 2020, representing the only approval for ADRB3.
The single approval suggests limited clinical success; further research is needed to validate ADRB3 as a viable target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (12 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 18 clinical trials targeting ADRB3.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities